📊 DERM Key Takeaways
Is Journey Medical Corp (DERM) a Good Investment?
Journey Medical Corp demonstrates severe fundamental weakness with consistent unprofitability, negative free cash flow of -$21.2M, and declining net margins of -22.2%. Despite $24.9M in cash, the company is burning capital at an unsustainable rate with no path to profitability evident from current operations.
Journey Medical’s fundamentals are weak: revenue growth is minimal while operating and net margins remain deeply negative, indicating the business is not converting sales into sustainable profitability. Liquidity is adequate in the near term, but persistent operating cash burn, very negative free cash flow, and weak interest coverage reduce financial flexibility and make the growth profile low quality.
Why Buy Journey Medical Corp Stock? DERM Key Strengths
- Adequate liquidity position with $24.9M cash and 1.42x current ratio
- Modest revenue growth of 1.8% YoY in a competitive pharmaceutical sector
- Manageable debt-to-equity ratio of 0.97x provides some financial flexibility
- Revenue is still growing modestly year over year, showing product demand has not collapsed
- Cash of $24.95M and a 1.42x current ratio provide some near-term liquidity support
- Debt/equity of 0.97x is meaningful but not yet extreme relative to equity base
DERM Stock Risks: Journey Medical Corp Investment Risks
- Severe cash burn with -$21.2M free cash flow limiting runway with existing cash reserves
- Persistently negative profitability across all metrics (operating margin -16.9%, net margin -22.2%)
- Negative interest coverage ratio of -3.2x indicates inability to service debt from operations
- Deteriorating EPS of -$0.43 with -242.9% YoY decline signals worsening per-share economics
- Large capital expenditures of $15.0M against negative operating cash flow suggests investments not yet generating returns
- High long-term debt of $25.2M relative to equity base creates refinancing risk
- Negative operating income, net income, and margins indicate an unprofitable core business
- Operating cash flow is negative and free cash flow is deeply negative, suggesting cash consumption is elevated
- Negative interest coverage and sizable long-term debt increase refinancing and balance-sheet risk if losses persist
Key Metrics to Watch
- Quarterly operating cash flow trend and path to cash flow breakeven
- Gross margin expansion and operating leverage as revenue scales
- Cash runway and timeline until additional funding becomes necessary
- Product-level profitability and customer acquisition costs
- Debt maturity schedule and refinancing requirements
- Operating cash flow trend and free cash flow improvement
- Operating margin improvement and interest coverage recovery
Journey Medical Corp (DERM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Journey Medical Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
DERM Profit Margin, ROE & Profitability Analysis
DERM vs Healthcare Sector: How Journey Medical Corp Compares
How Journey Medical Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Journey Medical Corp Stock Overvalued? DERM Valuation Analysis 2026
Based on fundamental analysis, Journey Medical Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Journey Medical Corp Balance Sheet: DERM Debt, Cash & Liquidity
DERM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Journey Medical Corp's revenue has remained relatively flat over the 5-year period, with a 3% decline. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
DERM Revenue Growth, EPS Growth & YoY Performance
DERM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.6M | -$2.3M | $-0.09 |
| Q2 2025 | $14.9M | -$3.4M | $-0.16 |
| Q1 2025 | $13.0M | -$4.1M | $-0.18 |
| Q3 2024 | $14.6M | -$1.7M | $-0.09 |
| Q2 2024 | $14.9M | -$3.4M | $-0.17 |
| Q1 2024 | $12.2M | -$10.1M | $-0.53 |
| Q3 2023 | $15.3M | -$1.7M | $-0.09 |
| Q2 2023 | $17.0M | -$7.5M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Journey Medical Corp Dividends, Buybacks & Capital Allocation
DERM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Journey Medical Corp (CIK: 0001867066)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DERM
What is the AI rating for DERM?
Journey Medical Corp (DERM) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DERM's key strengths?
Claude: Adequate liquidity position with $24.9M cash and 1.42x current ratio. Modest revenue growth of 1.8% YoY in a competitive pharmaceutical sector. ChatGPT: Revenue is still growing modestly year over year, showing product demand has not collapsed. Cash of $24.95M and a 1.42x current ratio provide some near-term liquidity support.
What are the risks of investing in DERM?
Claude: Severe cash burn with -$21.2M free cash flow limiting runway with existing cash reserves. Persistently negative profitability across all metrics (operating margin -16.9%, net margin -22.2%). ChatGPT: Negative operating income, net income, and margins indicate an unprofitable core business. Operating cash flow is negative and free cash flow is deeply negative, suggesting cash consumption is elevated.
What is DERM's revenue and growth?
Journey Medical Corp reported revenue of $45.8M.
Does DERM pay dividends?
Journey Medical Corp does not currently pay dividends.
Where can I find DERM SEC filings?
Official SEC filings for Journey Medical Corp (CIK: 0001867066) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DERM's EPS?
Journey Medical Corp has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DERM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Journey Medical Corp has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DERM stock overvalued or undervalued?
Valuation metrics for DERM: ROE of -39.3% (sector avg: 15%), net margin of -22.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DERM stock in 2026?
Our dual AI analysis gives Journey Medical Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DERM's free cash flow?
Journey Medical Corp's operating cash flow is $-6.2M, with capital expenditures of $15.0M. FCF margin is -46.2%.
How does DERM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -22.2% (avg: 12%), ROE -39.3% (avg: 15%), current ratio 1.42 (avg: 2).